AusperBio raises $50 million in Series B+ funding to advance a functional cure for chronic hepatitis B, led by an existing industry-leading investor.

May 28, 2025•2 months ago

Amount Raised

$50 Million

Round Type

SERIES B

San MateoBiopharmaTherapeuticsBiotechnologyHealth Care

Investors

Sherpa CapitalHan Kang CapitalYuan Bio Venture CapitalGenesis CapitalCdh InvestmentsQiming Venture Partners

Description

AusperBio has completed a $50 million Series B+ financing round to support its clinical development of AHB-137 for chronic hepatitis B. This round was oversubscribed and saw participation from several prominent investors. The funding will facilitate Phase II trials and commercial manufacturing partnerships. The successful financing underscores strong investor confidence in AusperBio's strategic direction.

Company Information

Company

AusperBio

Location

San Mateo, California, United States

About

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B. The company has developed a proprietary Med-OligoTM ASO platform with novel insights into ASO design and capabilities to substantially enhance the current ASO therapeutics. Combining with efficient targeted delivery conjugation technologies, the modular Med-OligosTM Platform empowers ASO therapeutics to treat broad viral infections, metabolic conditions, genetic disorders, and immune diseases.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends